China, which has chinese stocks bouncing today weve also got another big announcement as well dont miss the debut of a new segment here on closing bell today. The market zone is coming up into and after the close well bring you the stocks and stories every investor needs to know and it will look a little different as well. Joining us for the hour is mark tepper from Strategic Wealth partners mark, thanks for being here. Thanks for having me. Looking at the dow today, were up 154 points. The s p is also hovering right around 2980, it looks like a decent last day for the month of september as we head into these final three months of the year, what are you watching the most closely . I think the biggest catalyst right now is a potential trade deal all eyes are looking on this meeting next week between the u. S. And china, because if you think about it, its really, really difficult for ceos of publicly traded companies to execute on their growth plans if they have no visibility as to what
Dividends and buy backs for all major u. S. Banks financials rise ago cross the board in the free market. Drops its bid to buy rite aid buying stores instead. Rite aid shares are plunging because its future is called into question. Blue apron at the low end of a lowered range. The Amazon Effect and signals for an already slow year for ipos first up though stocks are looking to maintain upward momentum after the nasdaqs best day of the year and the saeps best day since april financials doing their part after the fed approved capital return requests for 34 of the largest u. S. Banks a lot of the hikes and capital returns that we saw yesterday mostly above expectations. The market just figured this out. Its been so well telegraphed that theres going to be good news but managements and boards and banks themselves were more aggressive on the buy back and dividend intentions and they all got approved i also think you cant separate it from bond yields. So its good news on capital return there
Swedish Orphan Biovitrum is acquiring CTI Biopharma in a $1.7 billion deal centered on the biotech’s commercialized drug for the blood cancer myelofibrosis. Sobi says the drug, Vonjo, complements one of its own assets approved for a different blood disorder.
Dublin, April 20, 2023 (GLOBE NEWSWIRE) The "Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics.